Land: Irland
Språk: engelsk
Kilde: HPRA (Health Products Regulatory Authority)
Calcium carbonate; Colecalciferol
PCO Manufacturing Ltd.
A12AA04
Calcium carbonate; Colecalciferol
Chewable tablet
calcium carbonate
2022-10-28
_ _ _ _ PACKAGE LEAFLET: INFORMATION FOR THE USER CALCICHEW ® -D 3 FORTE 500 MG/400 IU CHEWABLE TABLETS calcium/colecalciferol READ ALL OF THIS LEAFLET CAREFULLY BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Always take this medicine exactly as described in this leaflet or as your doctor or pharmacist have told you. Keep this leaflet. You may need to read it again. Ask your pharmacist if you need more information or advice. You must talk to a doctor if you do not feel better or if you feel worse after two weeks. If you get any side effects talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What Calcichew-D 3 Forte is and what it is used for 2. What you need to know before you take Calcichew-D 3 Forte 3. How to take Calcichew-D 3 Forte 4. Possible side effects 5. How to store Calcichew-D 3 Forte 6. Contents of the pack and other information 1 s and what it is used for 1. WHAT CALCICHEW-D 3 FORTE IS AND WHAT IT IS USED FOR Calcichew-D 3 Forte Chewable Tablets are lemon flavoured chewable tablets containing calcium and vitamin D 3 which are both important substances in bone formation. Both are found in the diet and vitamin D is also produced in the skin after exposure to the sun. Calcichew-D 3 Forte is used to treat and prevent vitamin D/calcium deficiency, which may occur when your diet or lifestyle does not provide enough, or when body requirements are increased. This medicine may also be prescribed or recommended for certain bone conditions, for example osteoporosis, or during pregnancy. 2. BEFORE YOU TAKE CALCICHEW-D 3 FORTE DO NOT TAKE CALCICHEW- D 3 FORTE CHEWABLE TABLETS IF YOU: are allergic to calcium, vitamin D, or any of the other ingredients of this medicine (listed in section 6) have severe kidney problems have a condition that causes excessive amounts of calcium in your blood or urine (hypercalcaemia or hypercalciuria) e.g. o renal (kidney failure) o cancer that has affected y Les hele dokumentet
Health Products Regulatory Authority 28 October 2022 CRN00D50V Page 1 of 2 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Calcichew-D3 Forte 500 mg/400 IU Chewable Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Per tablet: Calcium carbonate 1250 mg (equivalent to 500 mg of elemental calcium) Colecalciferol 400 IU (equivalent to 10 micrograms vitamin D3). Excipient(s) with known effect: isomalt (E953) and sucrose. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Chewable tablet. _Product imported from Spain:_ Round, white, uncoated and convex tablet. May have small specks. 4 CLINICAL PARTICULARS As per PA2239/013/002 5 PHARMACOLOGICAL PROPERTIES As per PA2239/013/002 6 PHARMACEUTICAL PARTICULARS 6.1 LIST OF EXCIPIENTS Xylitol (E967) Povidone Isomalt (E953) Flavouring (lemon) Fatty acid mono- and diglycerides Sucralose (E955) Magnesium stearate Sucrose Modified maize starch Triglycerides, medium-chain Sodium ascorbate Silica, colloidal anhydrous Tocopherol 6.2 INCOMPATIBILITIES Not applicable. 6.3 SHELF LIFE Health Products Regulatory Authority 28 October 2022 CRN00D50V Page 2 of 2 The shelf-life expiry date of this product is the date shown on the container and outer package of the product on the market in the country of origin. 6.4 SPECIAL PRECAUTIONS FOR STORAGE Do not store above 30 °C. Keep the container tightly closed to protect from moisture. 6.5 NATURE AND CONTENTS OF CONTAINER White, high density polyethylene bottles. Bottles of 60 chewable tablets contained in an outer cardboard carton. 6.6 SPECIAL PRECAUTIONS FOR DISPOSAL No special requirements. 7 PARALLEL PRODUCT AUTHORISATION HOLDER PCO Manufacturing Ltd., Unit 10, Ashbourne Business Park, Rath, Ashbourne, Co. Meath, Ireland 8 PARALLEL PRODUCT AUTHORISATION NUMBER PPA0465/156/003 9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 28 th October 2022 10 DATE OF REVISION OF THE TEXT Les hele dokumentet